Open an account

Inhibrx Biosciences

INBX · NASDAQ

$95.30+$5.51 (+6.14%)TodayMarket closed ·
Prev close $89.79

About INBX

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. The company is headquartered in La Jolla, California and currently employs 109 full-time employees. The company went IPO on 2024-05-28. The firm utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

Employees
109
Headquarters
La Jolla, California
Listed
May 28, 2024
Sector
Health Care
Industry
Biotechnology
Website
inhibrx.com

INBX key statistics

Market cap
1.40B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
228.38K
Volume
221.47K
Open price
$89.07
High today
$96.50
Low today
$88.99
52 Week high
$155.29
52 Week low
$28.16

Inhibrx Biosciences (INBX) at a glance

Inhibrx Biosciences (INBX) last traded at $95.30, with a market cap of 1.40B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $88.99 and $96.50. The current price is 7.1% above the day's low and 1.2% below its high.

Volume so far is 221.47K shares, in line with the average of 228.38K shares a day.

Over the past year Inhibrx Biosciences has ranged from $28.16 to $155.29, and now sits 53% of the way up that range.

Inhibrx Biosciences met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$2.34 per share against an estimate of -$2.44.

The average analyst price target is $272.00, 185.4% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $272.00
Low
$232.30
Now
$95.30
High
$341.25

INBX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 11.9% on average.

  1. Q3 FY24: reported -$2.84 per share against an estimate of -$3.45
  2. Q4 FY24: reported -$3.09 per share against an estimate of -$2.94
  3. Q1 FY25: reported -$2.80 per share against an estimate of -$2.90
  4. Q2 FY25: reported -$1.85 per share against an estimate of -$2.82
  5. Q3 FY25: reported -$2.28 per share against an estimate of -$1.75
  6. Q4 FY25: reported -$2.11 per share against an estimate of -$2.12
  7. Q1 FY26: reported -$2.15 per share against an estimate of -$1.82
  8. Q2 FY26: reported -$2.34 per share against an estimate of -$2.44

INBX news

  • Press releasePRNewswire

    Inhibrx Announces Participation in Upcoming Scientific Conferences

  • Vandana Singh

    Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

  • Press releasePRNewswire

    Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

  • Press releasePRNewswire

    Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

  • Press releasePRNewswire

    Inhibrx Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

  • Press releasePRNewswire

    Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

  • Press releasePRNewswire

    Inhibrx Reports First Quarter 2026 Financial Results

Similar companies

Companies in the same industry as Inhibrx Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.